The NbN was developed because it has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it appropriately inform the clinician about neuroscience-based prescribing. Very often we prescribe “antidepressants” for “anxiety” disorders or “second generation antipsychotics” to depressed patients.
This practice is confusing.
• The mission of NbN is to embed our current neuroscience advances in the nomenclature.
• The scope is to include all medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
This proposed nomenclature aims to reflect the current pharmacology knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled this app could have taken the stand that our current knowledge base is not enough to define the exact pharmacological domain or the correct mechanisms of action. However, as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. After all, we need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:-
1. The need to treat now
2. Updated neuroscience insights
3. The judgment of the members of the taskforce
4. The assumption that children are developing and therefore developmental aspects (e.g. liver and kidney function, brain developmental stage) must be considered in use and dosage.
Along these lines, we have come up with a nomenclature that is driven by: pharmacology and mode of action. The NbN reflects current knowledge and understanding regarding neurotransmitters / molecules / systems being modified + mode / mechanism of action

4 clinically relevant dimensions are also included:
1.Approved indications – Based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.) for this age group.
2. Efficacy and side effects – Aimed to highlight situations in which a compound has no formal approval for an indication, yet there is evidence to support its use in additional indication(s), for example well supported expert guidelines.
In the side effects section, only serious, life-changing or prevalent side-effects are listed.
3. “Practical notes” – Summarizes the clinical knowledge that has been "filtered" though the taskforce "sieve".
4. Neurobiology – Derived from empirical data.
For those who would like to know more about the pharmacology there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavor.

As this is an on-going process, we recognize that there are going to be omissions. Based on your feedback, other colleagues’ responses (the “wisdom of clinicians”), new reports and new findings, appropriate updates will be undertaken.

NbN C&A embeds current neuroscience advances in order to provide a comprehensive and coherent naming system for children and adolescence. The taskforce hopes that it will help clinicians to make informed decisions in their "psychopharmacological steps" and that it clarifies the rationale for prescribing.

国家宽带网的开发，因为它已经很清楚，精神药物的药理目前的命名没有反映我们当代的知识，也没有适当告知基于神经病学的处方医生。很多时候，我们规定了“焦虑”症或“第二代抗精神病药物”，以抑郁症患者“抗抑郁剂”。
这种做法是令人困惑的。
•的NbN的使命是嵌入在命名我们目前的神经科学的进步。
•范围是包括中枢神经系统的适应症所有的药物，并利用这种新的命名，以帮助时，他们正试图找出什么将是下一个合理的“neuropsychopharmacological一步”临床医生。
这个提议命名旨在反映当前的药理知识基础，并不能一定代表最终的科学道理。
在装配好这个程序的特别工作组可能采取的立场，我们目前的知识基础是不够的，定义确切的药理域或正确的行动机制。然而，作为一个工作小组，我们觉得这是更好地呈现尖端科学解释，而不是等待明确的结论。毕竟，我们现在需要把我们的病人，直到所有的事实都知道我们不能推迟治疗。
因此，该命名是基于： -
1.现在治疗的需要
2.更新神经科学的见解
3.特别工作组的成员的判断
4，儿童发展，因此发展方面的假设（如肝，肾功能，脑部发育阶段）必须在使用和用量考虑。
沿着这些线路，我们已经提出了由驱动的命名：药理和行为的模式。国家宽带网反映有关的神经递质/分子/系统是行动的修改+模式/机制目前的认识和了解

4种临床相关尺寸也包括在内：
1.Approved适应症 - 基于主要监管机构的这一年龄组的建议（如FDA，EMA等）。
2.疗效及副作用 - 针对突出，其中化合物具有指示没有正式批准，但有证据支持其在附加指示（）中使用，例如很好的支持专家指导的情况。
在副作用部分，只有严重的，改变生活或普遍的副作用上市。
3.“实用笔记” - 总结了临床知识已被“过滤”虽然工作小组“筛子”。
4.神经生物学 - 从经验数据导出的。
对于那些想了解更多关于药理学谁是有直接联系的IUPHAR相关网站 - 我们在这方面的合作者。

由于这是一个持续的过程，我们认识到将要遗漏。根据您的反馈，其他同事的回应（以下简称‘临床医生的智慧’），新报告和新的发现，适当的更新会进行。

的NbN C＆A嵌入，以提供对儿童和青少年的全面和一致的命名系统当前神经科学的进步。该工作小组希望，这将有助于临床医生做出明智的决定在他们的“精神药理学的步骤”，它明确了处方的合理性。